News
PBMWW
0.0180
0.00%
0.00
BUZZ-U.S. STOCKS ON THE MOVE-Micron, McDonald's, Generac
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Klaviyo, Frontier Group, Wabtec
Reuters · 1d ago
BUZZ-Psyence BioMed gains on dispute settlement with shareholder KAOS Capital
Reuters · 2d ago
Psyence Biomedical Settles Shareholder Litigation with KAOS Capital for $1.5 Million
Reuters · 2d ago
PSYENCE BIOMEDICAL LTD - SETTLEMENT TO BE FUNDED BY CASH ON HAND
Reuters · 2d ago
Weekly Report: what happened at PBMWW last week (0202-0206)?
Weekly Report · 4d ago
Weekly Report: what happened at PBMWW last week (0126-0130)?
Weekly Report · 02/02 09:14
Psyence Biomedical Announces 1-for-6.25 Reverse Stock Split Effective February 2
Reuters · 01/28 23:30
PSYENCE BIOMED ANNOUNCES EFFECTIVE DATE FOR 1-FOR-6.25 REVERSE STOCK SPLIT
Reuters · 01/28 23:30
Weekly Report: what happened at PBMWW last week (0119-0123)?
Weekly Report · 01/26 09:14
NASDAQ TRADE HALT CONTINUES <PBM.O> REASON NOT AVAILABLE AT 03:58 AM
Reuters · 01/21 08:58
Psyence BioMed Postpones Planned Reverse Stock Split
Reuters · 01/20 12:19
PSYENCE BIOMED ANNOUNCES POSTPONEMENT OF PREVIOUSLY ANNOUNCED REVERSE STOCK SPLIT EFFECTIVE DATE
Reuters · 01/20 12:19
Weekly Report: what happened at PBMWW last week (0112-0116)?
Weekly Report · 01/19 09:15
Psyence Biomedical Enacts 1-for-6.25 Reverse Stock Split
Reuters · 01/15 00:00
PSYENCE BIOMED ANNOUNCES EFFECTIVE DATE FOR 1-FOR-6.25 REVERSE STOCK SPLIT
Reuters · 01/15 00:00
Psyence BioMed Enacts 1-for-6.25 Reverse Stock Split
Reuters · 01/14 21:30
Psyence Biomedical Ltd. Announces 2026 Financial Strategy Including Potential Share Repurchase Program to Support Capital Management and Fund Clinical Milestones
Reuters · 01/13 12:59
PSYENCE BIOMED APPROVES 2026 FINANCIAL STRATEGY, BOARD AUTHORIZES SHARE BUYBACK ON VALUE OPPORTUNITY
Reuters · 01/12 13:30
Weekly Report: what happened at PBMWW last week (0105-0109)?
Weekly Report · 01/12 09:15
More
Webull provides a variety of real-time PBMWW stock news. You can receive the latest news about PSYENCE BIOMEDICAL LTD through multiple platforms. This information may help you make smarter investment decisions.
About PBMWW
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.